Handling SCD risk in adult congenital heart disease: Should we InVEST in the WCD?
作者信息
Narayanan Kumar
机构信息
Department of Cardiology/Electrophysiology, Medicover Hospitals, Behind Cyber Towers, Hitec City, Madhapur, Hyderabad, 500081, India.
出版信息
Indian Pacing Electrophysiol J. 2022 Sep-Oct;22(5):223-224. doi: 10.1016/j.ipej.2022.08.004.
Abstract
摘要
相似文献
1
Handling SCD risk in adult congenital heart disease: Should we InVEST in the WCD?应对成人先天性心脏病中的心脏性猝死风险：我们应该对可穿戴式心脏复律除颤器进行投资吗？
Indian Pacing Electrophysiol J. 2022 Sep-Oct;22(5):223-224. doi: 10.1016/j.ipej.2022.08.004.
2
Collaborative care for the wearable cardioverter defibrillator patient: Getting the patient and medical team "vested and active".可穿戴式除颤器患者的协作式护理：使患者和医疗团队“投入并积极参与”。
J Cardiovasc Electrophysiol. 2020 Sep;31(9):2509-2515. doi: 10.1111/jce.14708. Epub 2020 Aug 12.
3
Therapy optimization in patients with heart failure: the role of the wearable cardioverter-defibrillator in a real-world setting.心力衰竭患者的治疗优化：可穿戴式心脏复律除颤器在实际应用中的作用。
BMC Cardiovasc Disord. 2018 Mar 15;18(1):52. doi: 10.1186/s12872-018-0790-8.
4
Cost-minimization analysis of a wearable cardioverter defibrillator in adult patients undergoing ICD explant procedures: Clinical and economic implications.可穿戴式心脏除颤器在接受 ICD 除颤器取出术的成年患者中的成本最小化分析：临床和经济意义。
Clin Cardiol. 2021 Nov;44(11):1497-1505. doi: 10.1002/clc.23709. Epub 2021 Aug 24.
5
Real-world experience with the wearable cardioverter defibrillator: clinical effectiveness and wear-time adherence in patients at high risk for sudden cardiac death.可穿戴心脏除颤器的真实世界应用经验：高危心源性猝死患者的临床疗效和佩戴依从性。
Herzschrittmacherther Elektrophysiol. 2022 Mar;33(1):55-62. doi: 10.1007/s00399-021-00816-w. Epub 2021 Oct 25.
6
The wearable cardioverter-defibrillator in a real-world clinical setting: experience in 102 consecutive patients.真实临床环境中的可穿戴式心脏复律除颤器：102例连续患者的经验
Clin Res Cardiol. 2017 Apr;106(4):300-306. doi: 10.1007/s00392-016-1054-1. Epub 2016 Nov 25.
7
Wearable cardioverter-defibrillator as a bridge to cardiac transplantation: A national database analysis.可穿戴式心脏除颤器作为心脏移植的桥梁：国家数据库分析。
J Heart Lung Transplant. 2015 Oct;34(10):1305-9. doi: 10.1016/j.healun.2015.04.004. Epub 2015 May 4.
8
[Patients with a wearable cardioverter-defibrillator (WCD) : Prescription, function and rehabilitation support].[佩戴式心脏复律除颤器（WCD）患者：处方、功能及康复支持]
Herz. 2019 Aug;44(5):379-389. doi: 10.1007/s00059-017-4650-6. Epub 2017 Dec 12.
9
One-year follow-up of the prospective registry of patients using the wearable defibrillator (WEARIT-II Registry).使用可穿戴除颤器患者前瞻性注册研究（WEARIT-II注册研究）的一年随访
Pacing Clin Electrophysiol. 2018 Oct;41(10):1307-1313. doi: 10.1111/pace.13448. Epub 2018 Jul 26.
10
Use of the wearable cardioverter defibrillator in high-risk cardiac patients: data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry).可穿戴式心脏除颤器在高危心脏患者中的应用：来自前瞻性可穿戴式心脏除颤器（WEARIT-II 注册研究）患者使用登记数据库的数据。
Circulation. 2015 Oct 27;132(17):1613-9. doi: 10.1161/CIRCULATIONAHA.115.015677. Epub 2015 Aug 27.
本文引用的文献
1
Wearable cardioverter-defibrillator (life-vest): A feasible bridging treatment in adult congenital heart disease.可穿戴式心脏复律除颤器（救生背心）：成人先天性心脏病的一种可行的过渡治疗方法。
Indian Pacing Electrophysiol J. 2022 Sep-Oct;22(5):217-222. doi: 10.1016/j.ipej.2022.06.005. Epub 2022 Jun 28.
2
Wearable cardioverter-defibrillator in patients with a transient risk of sudden cardiac death: the WEARIT-France cohort study.可穿戴式心脏除颤器在有短暂性心源性猝死风险患者中的应用：WEARIT-France 队列研究。
Europace. 2021 Jan 27;23(1):73-81. doi: 10.1093/europace/euaa268.
3
Use of the wearable cardioverter-defibrillator - the Swiss experience.可穿戴式除颤器的使用——瑞士经验。
Swiss Med Wkly. 2020 Sep 30;150:w20343. doi: 10.4414/smw.2020.20343. eCollection 2020 Sep 21.
4
Long-Term Follow-Up of Patients With Tetralogy of Fallot and Implantable Cardioverter Defibrillator: The DAI-T4F Nationwide Registry.法洛四联症患者和植入式心脏复律除颤器的长期随访：DAI-T4F 全国注册研究。
Circulation. 2020 Oct 27;142(17):1612-1622. doi: 10.1161/CIRCULATIONAHA.120.046745. Epub 2020 Oct 1.
5
Implantable Cardioverter-defibrillators in Adult Congenital Heart Disease.成人先天性心脏病中的植入式心律转复除颤器
J Innov Card Rhythm Manag. 2018 Jun 15;9(6):3172-3181. doi: 10.19102/icrm.2018.090601. eCollection 2018 Jun.
6
Impact of wearable cardioverter-defibrillator compliance on outcomes in the VEST trial: As-treated and per-protocol analyses.可穿戴式除颤器依从性对 VEST 试验结果的影响：按治疗分析和意向性分析。
J Cardiovasc Electrophysiol. 2020 May;31(5):1009-1018. doi: 10.1111/jce.14404. Epub 2020 Mar 3.
7
Potential cost-effectiveness of wearable cardioverter-defibrillator for patients with implantable cardioverter-defibrillator explant in a high-income city of China.中国高收入城市中植入式心脏除颤器取出患者佩戴式心脏除颤器的潜在成本效益。
J Cardiovasc Electrophysiol. 2019 Nov;30(11):2387-2396. doi: 10.1111/jce.14153. Epub 2019 Sep 25.
8
Wearable cardioverter-defibrillators in pediatric cardiomyopathy: A cost-utility analysis.可穿戴式除颤器在儿科心肌病中的应用：成本效用分析。
Heart Rhythm. 2020 Feb;17(2):287-293. doi: 10.1016/j.hrthm.2019.08.028. Epub 2019 Aug 30.
9
Wearable Cardioverter-Defibrillator after Myocardial Infarction.心肌梗死后的可穿戴式心脏除颤器。
N Engl J Med. 2018 Sep 27;379(13):1205-1215. doi: 10.1056/NEJMoa1800781.
10
The US Experience of the Wearable Cardioverter-Defibrillator in Pediatric Patients.美国小儿患者应用可穿戴式心脏除颤器的经验。
Circ Arrhythm Electrophysiol. 2018 Jul;11(7):e006163. doi: 10.1161/CIRCEP.117.006163.
Zotero 插件